IHC results showed that the piperlongumine and osimertinib combination effectively downregulated the expression of Ki67, c-Met, and Sp1 in tumor tissues, leading to an extension in the survival time of mice (Figure 8, H and I). Here, MKI67 is linked to neoplasm.